SGD Pharma outlines its strategy to become a global market leader in pharmaceutical glass packaging.
CEO Olivier Rousseau said SGD Pharma intended to grow considerably in 2024, in areas such as innovation, industry, and sustainability.
Mr Rousseau said: “The start of 2023 brought a new partnership, with the announcement of our joint venture with Corning, supported by investment from the Telangana state in India.
“This collaboration combined Corning’s state-of-the-art coating technology with SGD Pharma’s glass-converting expertise to manufacture Velocity Vials, Type I borosilicate glass tubing.”
The construction of a new tubing plant officially began with a ground-breaking ceremony at the plant in Vemula, India, in June 2023.
On completion, this new facility will expand pharmaceutical packaging manufacturing in India, and increase access to the Corning Velocity Vial technology in the region.
Other site investments include the renovation of one of two furnaces at SGD Pharma’s Saint Quentin Lamotte (SQLM) plant in France.
This rebuild will contribute to a two-thirds reduction in the company’s total carbon emissions by 2040 and will cut the SQLM CO2 emissions by almost 20%.
A Memorandum of Understanding was also signed with the Zhanjiang Mayor in China.
This will allow SGD Pharma to rebuild the plant furnace at Zhanjiang, and a new siliconization operation line will become operational at the SQLM plant to increase flexibility and capacity.
SGD Pharma will also focus on decarbonisation, with planned reductions in emissions by -65% by 2040.
The company was awarded a gold EcoVadis sustainability rating, and was in the top 5% of glass product manufacturers after scoring highly in EcoVadis’ four key areas, which includes the environment and sustainable procurement.
At the end of the year, SGD Pharma also joined the Science Based Targets initiative (SBTi).
SGD Pharma’s plants in France, Germany, India and China plan to cut CO2 scope 1 and 2 emissions by 35% by 2030 and by 65% by 2040 (compared with a 2020 baseline).
